- Home
- SSBK vs ATYR Comparison
SSBK vs ATYR Comparison
Compare SSBK & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- ATYR
- Stock Information
- Founded
- SSBK 2007
- ATYR 2005
- Country
- SSBK United States
- ATYR United States
- Employees
- SSBK N/A
- ATYR N/A
- Industry
- SSBK Commercial Banks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSBK Finance
- ATYR Health Care
- Exchange
- SSBK Nasdaq
- ATYR Nasdaq
- Market Cap
- SSBK 330.0M
- ATYR 327.0M
- IPO Year
- SSBK 2021
- ATYR 2015
- Fundamental
- Price
- SSBK $32.62
- ATYR $3.27
- Analyst Decision
- SSBK Buy
- ATYR Strong Buy
- Analyst Count
- SSBK 1
- ATYR 6
- Target Price
- SSBK $36.00
- ATYR $18.60
- AVG Volume (30 Days)
- SSBK 14.0K
- ATYR 1.7M
- Earning Date
- SSBK 04-21-2025
- ATYR 03-13-2025
- Dividend Yield
- SSBK 1.10%
- ATYR N/A
- EPS Growth
- SSBK 3.77
- ATYR N/A
- EPS
- SSBK 3.67
- ATYR N/A
- Revenue
- SSBK $94,140,000.00
- ATYR $235,000.00
- Revenue This Year
- SSBK $19.13
- ATYR $1,387.23
- Revenue Next Year
- SSBK $7.78
- ATYR $873.22
- P/E Ratio
- SSBK $8.87
- ATYR N/A
- Revenue Growth
- SSBK 13.56
- ATYR N/A
- 52 Week Low
- SSBK $22.13
- ATYR $1.42
- 52 Week High
- SSBK $39.16
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- SSBK 53.23
- ATYR 44.59
- Support Level
- SSBK $32.11
- ATYR $3.63
- Resistance Level
- SSBK $33.00
- ATYR $3.94
- Average True Range (ATR)
- SSBK 0.75
- ATYR 0.33
- MACD
- SSBK 0.14
- ATYR -0.01
- Stochastic Oscillator
- SSBK 73.97
- ATYR 33.58
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.